SCHEMBL7220550

SCHEMBL7220550

COC(=O)c1cnn(-c2ccc(F)cc2)c1-c1ccncc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.48
ALDH1A1 P00352 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
FLT3 P36888 1/20 0.43
CCR1 P32246 1/20 0.43
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
CASP1 P29466 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
CYP46A1 Q9Y6A2 1/20 0.41
MAPK13 O15264 2/20 0.41
MAPK12 P53778 2/20 0.41
MAPK11 Q15759 2/20 0.41
DYRK1A Q13627 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7221298 0.85 MAPK14 (0.53) MAPK14ALDH1A1FLT3CCR1
SCHEMBL7215277 0.83 MAPK14 (0.54) MAPK14ALDH1A1FLT3CCR1
SCHEMBL7653232 0.82 PTGS2 (0.61)
SCHEMBL19120605 0.79 MEN1 (0.48) MAPK14ALDH1A1L3MBTL1CCR1HPGD
SCHEMBL19119916 0.78 L3MBTL1 (0.47) MAPK14ALDH1A1L3MBTL1CCR1HPGD
Acetic Acid SCHEMBL28878619 0.76 MAPK14 (0.44) MAPK14ALDH1A1FLT3CCR1MAPK13
SCHEMBL15790737 0.75 HSD11B1 (0.45) MAPK14ALDH1A1L3MBTL1CCR1HPGD
SCHEMBL5481730 0.74 ALDH1A1 (0.65) MAPK14ALDH1A1L3MBTL1HPGDTSHR
SCHEMBL15779573 0.73 ALDH1A1 (0.55) MAPK14ALDH1A1CCR1
SCHEMBL3822343 0.73 SPR (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6509361-B1 Inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase or PHARMACIA CORPORATION 2003-01-21 US disclosed
EP-1077971-A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 2001-02-28 EP disclosed
WO-1999058523-A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. SEARLE & CO. (US) 1999-11-18 WO disclosed